English name | Enzalutamide恩杂鲁胺 |
Synonyms | 4-{3-[4-cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-sulfanylideneiMidazolidin-1-yl}-2-fluoro-N-MethylbenzaMide;EnzalutaMide;MDV3100(EnzalutaMide);ENZALUTAMIDE;MDV-3100;MDV-3100;4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidChemicalbookinyl]-2-fluoro-N-methylbenzamide;4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide;MDV3100,4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluoro-N-MethylbenzaMide |
CAS | 915087-33-1 |
EINECS | 805-022-1 |
Molecular formula | C21H16F4N4O2S |
Molecular weight | 464.44 |
Chemical formula |
|
Content > | |
Density | 1.49 |
Melting point | 198 - 200°C |
Solubility | Soluble in DMSO (>25 mg/ml) |
Acidity coefficient | 13.88±0.46(Predicted) |
Storage condition | -20°C |
Appearance | solid |
Colour | White to off-white |
Stability | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
HS | 29339900 |
Use | Enheterolumide can be used in almost all stages of prostate cancer, such as advanced patients before chemotherapy, can significantly delay the start of chemotherapy time in patients. In addition, it can significantly improve the overall survival time and progression-free survival time of patients with CRPC and mCRPC after chemotherapy. |
Package | （According to user requirements） |
Upstream raw materials | N - methyl - 4 - bromine - 2 - fluoro - 4 - the cyanide and benzamide acyl - 2 - (three fluorinated methyl) cyanobenzene 4 - [(2 - cyano - 2 - c) amino] - 2 - fluoro - N - methyl benzamide N - [Chemicalbook3 - fluoro - 4 - [(methyl amino) carbonyl] phenyl] 2 - methyl - alanine methyl 1289942-5 5-7N-[3-fluoro-4 -[(methyl amino) carbonyl] phenyl] -2-methylalanine
|
